EST79232 and EST79376, Two novel sigma-1 receptor ligands, exert neuroprotection on models of motoneuron degeneration

Motor neuron diseases (MNDs) include sporadic and hereditary neurological disorders characterized by progressive degeneration of motor neurons (MNs). Sigma-1 receptor (Sig-1R) is a protein enriched in MNs, and mutations on its gene lead to various types of MND. Previous studies have suggested that S...

Descripción completa

Detalles Bibliográficos
Autores: Gaja Capdevila, Núria|||0000-0002-0028-570X, Hernández, Neus, Yeste, Sandra, Reinoso, Raquel, Burgueño, Javier, Montero, Ana, Merlos, Manuel, Vela, José M., Herrando-Grabulosa, Mireia|||0000-0002-6685-3220, Navarro, X. (Xavier)|||0000-0001-9849-902X
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:260278
Acceso en línea:https://ddd.uab.cat/record/260278
https://dx.doi.org/urn:doi:10.3390/ijms23126737
Access Level:acceso abierto
Palabra clave:Amyotrophic lateral sclerosis
Motoneuron degeneration
Sigma-1 receptor
SOD1G93A mice
Spinal nerve injury
Descripción
Sumario:Motor neuron diseases (MNDs) include sporadic and hereditary neurological disorders characterized by progressive degeneration of motor neurons (MNs). Sigma-1 receptor (Sig-1R) is a protein enriched in MNs, and mutations on its gene lead to various types of MND. Previous studies have suggested that Sig-1R is a target to prevent MN degeneration. In this study, two novel synthesized Sig-1R ligands, coded EST79232 and EST79376, from the same chemical series, with the same scaffold and similar physicochemical properties but opposite functionality on Sig-1R, were evaluated as neuroprotective compounds to prevent MN degeneration. We used an in vitro model of spinal cord organotypic cultures under chronic excitotoxicity and two in vivo models, the spinal nerve injury and the superoxide dismutase 1 (SOD1)G93A mice, to characterize the effects of these Sig-1R ligands on MN survival and modulation of glial reactivity. The antagonist EST79376 preserved MNs in vitro and after spinal nerve injury but was not able to improve MN death in SOD1G93A mice. In contrast, the agonist EST79232 significantly increased MN survival in the three models of MN degeneration evaluated and had a mild beneficial effect on motor function in SOD1G93A mice. In vivo, Sig-1R ligand EST79232 had a more potent effect on preventing MN degeneration than EST79376. These data further support the interest in Sig-1R as a therapeutic target for neurodegeneration.